Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Presentation of Q2 interim report 2023

By Michael FriisHead of Equities
ExpreS2ion Biotech Holding

Today, ExpreS2ion Biotechnologies released its Q2 2023 results and, more importantly, announced a review of its strategy, pipeline, and organization to materially extend the runway in a tight funding market. This includes, among others, a pause of the breast cancer candidate. With focus on the strategy announcement, the company’s CEO Bent Frandsen and CFO Keith Alexander presented the implications and potential effect of the strategy review, noting that this is in the first inning. 


ExpreS2ion Biotechnologies is a Danish biotechnology company, which focuses on the development of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system.

 

HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 13.30 PM 28-04-2023.

Recent videos

Rapala H2'25: North American sales a highlight of the end of the year
12.03.2026 klo 17.25 Rapala VMC
Columbus – Presentation of Annual Report 2025
12.03.2026 klo 14.00 Columbus
Tokmanni Q4’25: Dollarstore’s turnaround is stalling
12.03.2026 klo 13.02 Tokmanni Group
Multitude, Webcast, Q4'25
12.03.2026 klo 11.00 Multitude
Rapala VMC Oyj, Audiocast, Q4'25
12.03.2026 klo 11.00 Rapala VMC
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.